logo
Plus   Neg
Share
Email

Bayer And Atara Biotherapeutics Collaborate For Mesothelin-Targeted CAR T-cell Therapies

Bayer (BAYZF.PK,BAYRY.PK,BYR.L) and Atara Biotherapeutics, Inc. (ATRA) announced
worldwide license deal and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors.

Under deal, Atara will receive upfront payment of $60 million, and up to a total of $610 million for development, regulatory and commercialization milestones, plus tiered royalties up to low double-digit percentage of net sales.

Under deal terms, Atara will lead IND-enabling studies and process development for ATA3271, an armored allogeneic T-cell immunotherapy, while Bayer will be responsible for submitting the IND and subsequent clinical development and commercialization.

Atara will continue to be responsible for ongoing ATA2271 phase 1 study for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

As part of the transaction, Atara will provide translational and clinical manufacturing services to be reimbursed by Bayer. In addition, for a limited period of time, Bayer has a non-exclusive right to negotiate a license for additional Atara CAR T product candidates.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mediterranean Food Inc is recalling its "Alqosh Sesame Oil" citing the potential to be contaminated with Salmonella, the U.S. Food and Drug Administration said. The affected Alqosh Sesame Oil "Tahin" comes in a 2Lb, clear plastic jar marked with lot # 16082020 on the side of the jar and with a Production date of 08/16/2020 stamped on the side. Twitter has filed a lawsuit against Texas Attorney General Ken Paxton, seeking to halt his ongoing investigation into the company's content moderation practices. Paxton, a Republican and supporter of former president Donald Trump, on January 13 had sent a civil investigative demand or CID to Twitter after its decision to permanently suspend Trump from the social media platform... The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test.
Follow RTT